Investment Rating - The investment rating for the company is "Outperform the Market" [6][4][32] Core Views - The company is expected to achieve significant revenue growth in 2024, with projected revenue of CNY 240.19 billion, representing a year-on-year increase of 34% [9][11] - The net profit attributable to shareholders for 2024 is forecasted to be CNY 16.63 billion, a substantial increase of 213.32% compared to the previous year [11][9] - The company is focusing on a strategic shift towards AI and intelligent driving technologies, with the launch of the "Qianli Haohan" system aimed at enhancing its product offerings [24][26] Financial Performance - In 2024, the company achieved total sales of 2.177 million vehicles, a 32% increase year-on-year, with 41% of sales coming from new energy vehicles [2][16] - The gross margin for 2024 is reported at 15.9%, with a period expense ratio of 11.91% [13][11] - The company’s revenue from complete vehicle sales reached CNY 203.06 billion, reflecting a 36% year-on-year growth [16][2] Future Projections - For 2025, the company aims for a sales target of 2.71 million vehicles, including 1.5 million new energy vehicles [3][22] - The projected revenue for 2025 is CNY 309.74 billion, with a net profit forecast of CNY 13.7 billion [34][4] - The company plans to launch multiple new models across its brands, including the Galaxy, Zeekr, and Lynk & Co, enhancing its market presence [22][3] Valuation Metrics - The estimated earnings per share (EPS) for 2025 is projected to be CNY 1.36, with a price-to-earnings (P/E) ratio of 14-16 times [34][4] - The company’s reasonable valuation range is set between HKD 20.43 and HKD 23.34, indicating a potential upside from the current share price [6][34] - The company’s net asset return (ROE) is expected to be 13.6% in 2025, reflecting strong profitability [5][34]

Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 35.82 HKD compared to the current price of 22.55 HKD [4][7]. Core Insights - The company achieved total revenue of 630 million USD in 2024, a decrease of 24% year-on-year, with oncology product revenue increasing by 67% to 271.5 million USD [2][4]. - The overseas sales of Furuzakl® have significantly increased, with a 1450% rise in revenue to 110.8 million USD, while sales in China grew by 6% to 86.3 million USD [7]. - The company has successfully expanded its commercial products into new regions and indications, with multiple approvals for Furuzakl® in various countries [7]. - The ATTC platform is set to enter clinical trials in the second half of 2025, showcasing promising early data [7]. - The company expects revenue growth in the coming years, with projected revenues of 655 million USD in 2025, 821 million USD in 2026, and 934 million USD in 2027, reflecting growth rates of 4.0%, 25.2%, and 13.8% respectively [7]. Financial Summary - The company reported a net profit of 37.7 million USD for 2024, with a cash balance of 836.1 million USD as of December 31, 2024 [2]. - The projected earnings per share (EPS) for 2025 is 0.34 CNY, with a price-to-earnings (P/E) ratio of 8.5 [4]. - The company’s total assets are expected to grow from 1.27 billion USD in 2024 to 2.06 billion USD by 2027 [8].

Investment Rating - The investment rating for Meituan-W (03690.HK) is "Outperform the Market" [6][19]. Core Views - The core business of Meituan is experiencing robust growth, with overseas expansion accelerating to support medium-term growth [1][5]. - In Q4 2024, the company reported an adjusted net profit of 9.85 billion yuan, which is in line with expectations, while revenue reached 88.49 billion yuan, reflecting a year-on-year growth of 20.1% [1][9]. - The adjusted net profit for the full year 2024 is projected to be 43.77 billion yuan, representing an 88.2% increase year-on-year, driven by improved efficiency in core operations and reduced losses in new businesses [1][9]. Summary by Sections Core Local Business - In Q4 2024, the core local business generated revenue of 65.57 billion yuan, up 18.9%, with operating profit reaching 12.90 billion yuan, a 60.9% increase [2][11]. - The operating profit margin improved to 19.7%, up 5.2 percentage points year-on-year, exceeding Bloomberg's expectations [2][11]. - The delivery service and commission revenue grew by 19.5% and 23.9% respectively, while online marketing services saw a 17.7% increase [2][11]. New Business - New business revenue in Q4 2024 was 22.92 billion yuan, a 23.5% increase, with significant growth in commission and online marketing [3][16]. - The operating loss for new businesses narrowed significantly to 2.18 billion yuan, down from 4.83 billion yuan in Q4 2023, indicating improved efficiency [3][16]. - The Meituan Youxuan segment showed notable improvement in loss reduction, while Keeta remains a primary source of increased losses due to its early-stage investment phase [3][16]. Technology and Efficiency - The company is actively integrating AI technologies to enhance employee efficiency and service upgrades, with a focus on self-developed models [4][18]. - The "Shen Huai Yuan" program has expanded to cover multiple categories, increasing cross-selling opportunities and consumer engagement [4][18]. - The gradual implementation of social security for delivery personnel is expected to increase costs but may also enhance operational efficiency in the long run [4][18]. Financial Forecasts - Revenue for 2024 is projected at 337.59 billion yuan, with a year-on-year growth of 22.0%, and adjusted net profit is expected to reach 43.77 billion yuan [8][20]. - The adjusted net profit forecast for 2025 has been slightly reduced to 51.52 billion yuan, while the 2026 forecast has been raised to 65.31 billion yuan [5][19]. - The company is expected to maintain a strong growth trajectory, supported by ongoing improvements in online penetration and expansion into new markets [5][19].

证券研究报告 泡泡玛特 (9992 HK) 港股通 新品类及全球化势能强劲，上调盈利预测 | 华泰研究 | | | 年报点评 | | --- | --- | --- | --- | | 2025 年 | 3 月 | 27 日│中国香港 | 消费轻工 | 公司 24 年收入 130.4 亿元，同增 106.9%；经调整净利润 34.0 亿元，同增 185.9%，高于我们预期（30.1 亿元），主因搪胶毛绒加速放量，经营杠杆释 放超预期。H2 营收同增 143.2%，经调整净利同增 264.1%。25 年指引积 极，公司凭借成熟的 IP 运营平台，推动品牌形象在全球成为时尚潮流代名 词，25 年新品类、海外扩张驱动强劲，中长期新业务持续落地，多元变现 潜力广阔。看好公司成长为全球级潮玩龙头，维持"买入"评级。 搪胶毛绒等品类创新及全球拓展势能强劲，继续成为业绩的核心驱动力 1）分品类看，H2 手办、毛绒、MEGA、衍生品增速分别达 55.5%/1362.9%/ 148.4%/454.3%，毛绒加速放量，营收占比环增 18.4pct 至 28.1%。搪胶毛 绒成为时尚单品，"包挂"风潮加速粉丝破圈，助力全年会员同增 ...

港股公司报告 | 公司点评 珍酒李渡（06979） 证券研究报告 24H2 着眼长线主动降速，25 年高质量增长可期 事件：公司发布 2024 年年报。2024 年公司收入/归母净利润/经调净利润 分别为 70.67/13.24/16.76 亿元（同比+0.5%/-43.1%/+3.3%），其中 2024H2 公司收入/归母净利润/经调净利润分别为 29.34/5.72/6.58 亿元（同比 -16.5%/-22.9%/-19.8%）。 24H2 主动去库保证渠道良性，高端聚焦主品结构阶段承压。2024H2 公司 实现营收 29.34 亿元（同比-16.46%），销量/吨价分别同比-16.79%/+0.40%。 | 投资评级 | | | --- | --- | | 行业 | 必需性消费/食物饮品 | | 6 个月评级 | 买入（维持评级） | | 当前价格 | 7.26 港元 | | 目标价格 | 港元 | 分品牌看，2024H2 珍酒/李渡/湘窖/开口笑营收分别为 17.77/6.38/3.50/1.13 亿元（同比-21.95%/+2.91%/-10.64%/-31.02%）。 分价格带看，2024H2 ...

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [6]. Core Views - The company has reported a revenue of 28.7 billion RMB for 2024, representing a 15% year-on-year increase, driven by growth in demand from the mainland China and US sports brands [1]. - The gross profit margin for 2024 is 28.1%, an increase of 3.8 percentage points, with net profit rising by 37% to 6.2 billion RMB [1]. - The company is optimistic about its future growth, having emerged from a low point in operations and is focusing on enhancing core competitiveness and long-term development [4]. Summary by Sections Financial Performance - Revenue breakdown: Sports products account for 69% of total revenue with a 10% increase, leisure products 25% with a 27% increase, and underwear 5% with a 35% increase [1]. - Major clients: Client A generated 8 billion RMB (up 33%), Client B 7.4 billion RMB (down 4%), and Client C 5 billion RMB (up 35%) [1]. - The company plans to maintain a dividend payout ratio of approximately 56% [1]. Operational Efficiency - The company has restored its production capacity utilization to normal levels, with increased employee numbers and improved production efficiency [2][3]. - New factories in Cambodia and Vietnam are expected to enhance production capacity, with the Cambodian factory projected to employ around 6,000 workers [2]. Market Strategy - The company is focusing on diversifying its product offerings and enhancing supply chain management to improve competitiveness [2][5]. - Plans to increase market demand through new product development and optimizing production allocation based on customer needs are in place [5]. Future Outlook - The company anticipates continued growth despite challenges such as market demand weakness and rising manufacturing costs [4]. - It aims to leverage artificial intelligence and automation to enhance production processes and respond quickly to customer demands [4].

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [2]. Core Insights - The company reported a revenue of 42.75 billion yuan for 2024, representing a year-on-year growth of 3.1%, and a net profit attributable to shareholders of 4.71 billion yuan, up 4.6% year-on-year. The core operating profit for 2024 was 6.23 billion yuan, reflecting an 18.7% increase year-on-year, with a core operating profit margin of 14.6%, an increase of 1.9 percentage points [4][7]. - The company anticipates a year-end dividend of 2.53 billion yuan, with an overall dividend payout ratio of approximately 95%, corresponding to a dividend yield of about 5% [4][7]. Revenue Breakdown - The restaurant operating revenue was 40.40 billion yuan, a 2.9% increase year-on-year, with revenue contributions from first, second, third-tier cities, and Hong Kong/Macau/Taiwan at 17.7%, 38.7%, 40.0%, and 3.6% respectively. Other restaurant revenue grew by 39.6% to 480 million yuan, driven by the "Pomegranate Plan" and various innovative dining brands [5]. - The takeaway business generated 1.25 billion yuan, up 20.4% year-on-year, attributed to the launch of a single-person meal service in the second half of 2023. Sales from condiments and ingredients decreased by 27.1% to 580 million yuan [5]. Brand Development and Performance - As of the end of 2024, the company operated a total of 1,368 restaurants, including 1,355 self-operated and 13 franchised, with 62 new openings and 70 closures or relocations. The introduction of a franchise model has seen over 70% of applications coming from third-tier cities and below [6]. - The average customer spending was 97.5 yuan, a decrease of approximately 1.6% year-on-year, while the average table turnover rate was 4.1 times per day, an increase of 0.3 times per day [6]. Cost and Profitability Analysis - The cost of raw materials and consumables decreased by 4.3% to 16.21 billion yuan, accounting for 37.9% of revenue, while employee costs rose by 8.2% to 14.11 billion yuan, making up 33.0% of revenue [7]. - The company expects continued improvements in single-store efficiency and accelerated expansion through its franchise strategy and brand incubation, projecting net profits of 5.15 billion yuan, 5.59 billion yuan, and 6.07 billion yuan for 2025-2027, with respective year-on-year growth rates of 9.3%, 8.6%, and 8.5% [7][10]. Valuation and Price Target - The reasonable value range for the stock is estimated between 19.4 and 23.0 Hong Kong dollars per share, based on a 20-23 times PE ratio and a 10-12 times EV/EBITDA ratio for 2025 [7][10].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [3][10]. Core Insights - The company reported a revenue of 3.77 billion yuan for 2024, a year-on-year increase of 10.8%, with generative AI revenue reaching 2.4 billion yuan, growing by 103.1% [1]. - Adjusted net loss narrowed to 4.25 billion yuan from 5.41 billion yuan in the previous year [1]. - Revenue projections for 2025-2027 are estimated at 5.069 billion yuan, 6.920 billion yuan, and 9.538 billion yuan, reflecting growth rates of 34.38%, 36.51%, and 37.84% respectively [3]. Financial Performance - The company’s operating income for 2024 is projected to be 3.772 billion yuan, with a growth rate of 10.75% [6]. - The adjusted net profit for 2025 is expected to be -3.783 billion yuan, improving from -4.278 billion yuan in 2024, indicating a growth of 11.57% [3][6]. - The research indicates a decrease in sales, management, and R&D expense ratios, with R&D expense ratio at 109.5%, up by 7.8 percentage points year-on-year [2]. Business Strategy - The company is advancing a "large device - large model - application" strategy, focusing on AI visual and intelligent driving businesses, which saw revenue declines of 39.5% and 33.2% respectively [2]. - The AI visual customer repurchase rate increased by 31 percentage points, and the company is expanding into Southeast Asia and the Middle East [2]. - The company delivered 1.67 million units of its product, a 9.2% increase year-on-year, and plans to mass-produce a collaboration with Dongfeng Intelligent Driving in 2025 [2]. Valuation Metrics - The projected price-to-sales (P/S) ratios for 2025, 2026, and 2027 are 11.61, 8.50, and 6.17 respectively [3][6]. - The diluted earnings per share (EPS) is expected to improve from -0.12 yuan in 2024 to -0.06 yuan in 2027 [6].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has shown significant improvement in profit margins and continues to expand its store presence in lower-tier markets [7] - For the fiscal year 2024, the company reported total revenue of 24.83 billion RMB, a year-on-year increase of 22.3%, and a net profit of 4.44 billion RMB, up 41.4% year-on-year [7] - The company has established a robust end-to-end supply chain system and is focusing on brand marketing to strengthen its market position [7] Financial Performance Summary - Total revenue projections for the company are as follows: 2023A: 20.30 billion RMB, 2024A: 24.83 billion RMB, 2025E: 28.28 billion RMB, 2026E: 31.99 billion RMB, 2027E: 35.90 billion RMB [1] - Net profit projections are: 2023A: 3.14 billion RMB, 2024A: 4.44 billion RMB, 2025E: 5.37 billion RMB, 2026E: 6.09 billion RMB, 2027E: 6.88 billion RMB [1] - The company’s earnings per share (EPS) are projected to increase from 8.26 RMB in 2023A to 18.12 RMB in 2027E [1] Store Expansion and Market Presence - As of the end of 2024, the company had 41,600 stores in mainland China, a 25% year-on-year increase, and 4,895 overseas stores, a 13% year-on-year increase [7] - The company opened 10,555 new stores in 2024 while closing 1,609, resulting in a net increase of 8,946 stores [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has successfully transitioned to commercialization, with significant revenue growth expected from the drug Lukanosatuzumab, which was approved in China on November 22, 2024. The total revenue for 2024 is projected to be 1.933 billion yuan, representing a year-on-year growth of 25.5% [6] - The company reported a net loss of 267 million yuan for 2024, a reduction of 53.5% compared to the previous year, indicating improved financial performance [6] - The approval of Lukanosatuzumab for two indications in China and ongoing global clinical trials in collaboration with MSD highlight the company's strong pipeline and potential for future growth [6][7] - Financial forecasts have been adjusted, with expected net losses of 707 million yuan in 2025, 492 million yuan in 2026, and a profit of 512 million yuan in 2027, reflecting a positive outlook for the company's profitability trajectory [6] Financial Summary - Total revenue (in million yuan) is projected as follows: 2023: 1,540; 2024: 1,933; 2025: 1,690; 2026: 2,496; 2027: 4,101 [9] - The gross margin is expected to improve from 49.3% in 2023 to 82.0% by 2027, indicating enhanced operational efficiency [9] - The net profit margin is projected to turn positive by 2027, with a net profit margin of 12.5% [9] - The company's earnings per share (EPS) is expected to improve from -2.5 yuan in 2023 to 2.3 yuan in 2027 [9] Pipeline and Catalysts - The company is expected to receive approval for additional indications of Lukanosatuzumab in 2025, including 2L HR+Her2- breast cancer and other first-line indications anticipated for NDA submission in 2026 [8] - A166, another drug in the pipeline, is expected to receive approval for HER2+ breast cancer in the first half of 2025 [8]